Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe (Schering-Plough).

C Q Meng1

  • 1AtheroGenics Inc, Alpharetta, GA 30004, USA. cmeng@atherogenics.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Restenosis drug discovery--a formidable task.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Nitrobenzene compounds inhibit expression of VCAM-1.

Bioorganic & medicinal chemistry letters·2001
Same author

5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.

Bioorganic & medicinal chemistry letters·2000
Same author

5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.

Bioorganic & medicinal chemistry letters·2000
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Ezetimibe, a cholesterol absorption inhibitor, shows promise in treating high cholesterol. When combined with simvastatin, it significantly enhances LDL reduction compared to simvastatin alone.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ezetimibe (Sch-58235) is a novel cholesterol absorption inhibitor.
  • It is being developed for atherosclerosis and hypercholesterolemia treatment.
  • Ezetimibe was in phase III trials by January 2000.

Purpose of the Study:

  • To evaluate ezetimibe as a monotherapy for lipid lowering.
  • To explore combination therapy with statins (HMG-CoA reductase inhibitors).
  • To assess the additive effects of inhibiting cholesterol absorption and production.

Main Methods:

  • Clinical trials (Phase III) for ezetimibe monotherapy.
  • Development of a fixed-combination tablet with simvastatin.
  • Comparative analysis of lipid reduction between combination therapy and monotherapy.

Related Experiment Videos

Main Results:

  • Ezetimibe is studied as a monotherapy and in combination with statins.
  • A fixed-combination tablet with simvastatin (Zocor) was planned for US market by May 2000.
  • The combination improved LDL reduction to 52% versus 35% with Zocor alone.

Conclusions:

  • Ezetimibe demonstrates potential as an adjunct therapy to statins.
  • Combination therapy offers enhanced LDL reduction.
  • Ezetimibe and statins provide complementary mechanisms for cholesterol management.